Akèy › Lukemi miyoyid nan faz kwonik › Texas
Etid klinik pou Lukemi miyoyid nan faz kwonik nan Texas
6 etid pou Lukemi miyoyid nan faz kwonik ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT01746836Study of Olverembatinib (HQP1351) in Patients With CML-CP
- Ascentage Investigative Site #1051, Amarillo
- Ascentage Investigative Site #1036, Austin
- Ascentage Investigative Site #1501, Houston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06423911Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 15 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT02727803A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
- Baylor Scott and White Research, Temple
Ap rekriteEtid obsèvasyon
Laj 18 a 100 · Tout sèks · Mizajou Jul 20, 2026 · NCT07091019A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
- The University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 1, 2026 · NCT05304377A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
- The University of Texas M.D. Anderson Cancer Center, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jan 12, 2026 · NCT06163430Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.